Xemed — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Xemed is a private, product-focused diagnostic company pioneering hyperpolarized xenon-129 (129Xe) MRI for pulmonary functional imaging. Its core technology platform includes the MagniXene® investigational drug and the XeBox-E10 polarizer system, which together enable visualization of lung ventilation and gas exchange. The company is in the clinical stage, collaborating with major academic centers to validate its technology for indications like COPD, asthma, and lung cancer, aiming to provide non-invasive, radiation-free diagnostic tools. Xemed operates as a pre-revenue entity, advancing its programs through research partnerships and regulatory filings.

Respiratory DiseasesCOPDAsthmaLung Cancer

Technology Platform

Hyperpolarized Xenon-129 (129Xe) production and MRI imaging platform. Includes the MagniXene® investigational drug (hyperpolarized 129Xe gas) and the XeBox-E10 automated polarizer system. Technology leverages xenon's chemical shift to distinguish between gas phase and dissolved phase in lungs, enabling functional imaging of ventilation and gas exchange.

Opportunities

The technology addresses a major gap in respiratory care by providing a non-invasive, radiation-free method to regionally assess lung function and gas exchange, which is impossible with CT or standard PFTs.

This creates opportunities for early disease detection, personalized treatment planning in asthma and COPD, and serving as a biomarker for pharmaceutical drug development trials.

Risk Factors

The primary risks are regulatory, as obtaining FDA approval for a novel diagnostic gas agent is complex and uncertain.

Market adoption is also a risk due to the need for specialized MRI expertise and potential high cost.

The company's pre-revenue status and reliance on partnerships make it vulnerable to funding constraints.

Competitive Landscape

Competition in hyperpolarized gas MRI includes academic research groups and a few small companies focusing on helium-3 or xenon-129. Xemed differentiates with its integrated drug-device platform (MagniXene® + XeBox) and strong IP. Broader competition comes from established functional imaging modalities like nuclear medicine (V/Q scans) and emerging CT perfusion techniques, but none offer xenon MRI's unique combination of ventilation and dissolved-phase imaging without ionizing radiation.

More companies in Diagnostics & Precision Medicine →More companies in United States →